![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The acquisition includes four technologies for production of three generic drugs in tablet form, including Vinpocetine, Menthyl Valerate, Metamizole Sodium and one dietary supplement, Tribulus Terrestris Herba Extractum Siccum.
Lead Product(s): Vinpocetine
Therapeutic Area: Neurology Product Name: Vinpocetine-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Nika Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 15, 2024